- Home
- BIIB vs ROL Comparison
BIIB vs ROL Comparison
Compare BIIB & ROL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- ROL
- Stock Information
- Founded
- BIIB 1978
- ROL 1948
- Country
- BIIB United States
- ROL United States
- Employees
- BIIB N/A
- ROL N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- ROL Diversified Commercial Services
- Sector
- BIIB Health Care
- ROL Finance
- Exchange
- BIIB Nasdaq
- ROL Nasdaq
- Market Cap
- BIIB 18.8B
- ROL 27.6B
- IPO Year
- BIIB 1991
- ROL N/A
- Fundamental
- Price
- BIIB $133.99
- ROL $55.26
- Analyst Decision
- BIIB Buy
- ROL Buy
- Analyst Count
- BIIB 27
- ROL 8
- Target Price
- BIIB $188.17
- ROL $59.50
- AVG Volume (30 Days)
- BIIB 1.3M
- ROL 1.6M
- Earning Date
- BIIB 07-31-2025
- ROL 07-23-2025
- Dividend Yield
- BIIB N/A
- ROL 1.20%
- EPS Growth
- BIIB 26.39
- ROL 9.41
- EPS
- BIIB 10.12
- ROL 0.99
- Revenue
- BIIB $9,816,400,000.00
- ROL $3,462,863,000.00
- Revenue This Year
- BIIB N/A
- ROL $11.84
- Revenue Next Year
- BIIB N/A
- ROL $8.58
- P/E Ratio
- BIIB $13.29
- ROL $56.01
- Revenue Growth
- BIIB 1.59
- ROL 9.46
- 52 Week Low
- BIIB $110.04
- ROL $45.34
- 52 Week High
- BIIB $238.00
- ROL $58.65
- Technical
- Relative Strength Index (RSI)
- BIIB 56.84
- ROL 41.37
- Support Level
- BIIB $129.08
- ROL $55.04
- Resistance Level
- BIIB $137.84
- ROL $55.96
- Average True Range (ATR)
- BIIB 4.01
- ROL 0.96
- MACD
- BIIB 0.57
- ROL -0.13
- Stochastic Oscillator
- BIIB 70.81
- ROL 14.42
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About ROL Rollins Inc.
Rollins is a global leader in route-based pest control services, with operations primarily in the United States, as well as in North, Central, and South America, Europe, the Middle East, Africa, and Australia. Its portfolio of pest-control brands includes the prominent Orkin brand, a market leader in the US, which boasts near national coverage, and in Canada. Residential pest and termite prevention dominates the services provided by Rollins, owing to the group's ongoing focus on the US and Canadian markets.